Dr. Rimm is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
310 Cedar St
# Lauder
New Haven, CT 06510Phone+1 203-785-3624Fax+1 203-785-7037
Education & Training
- Yale-New Haven Medical CenterResidency, Pathology-Anatomic and Clinical, 1989 - 1993
- Johns Hopkins University School of MedicineClass of 1989
- University of Wisconsin-MadisonB.S., with Honors, 1977 - 1981
Certifications & Licensure
- CT State Medical License 1992 - 2025
- American Board of Pathology Anatomic Pathology
- American Board of Pathology Cytopathology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2014
- Top Doctors: New York Metro Area Castle Connolly, 2014
- America's Top Doctors for Cancer Castle Connolly, 2013
- Join now to see all
Clinical Trials
- S9313A Protein Expression Analysis of Breast Cancer Tissue Microarrays From Clinical Trial SWOG-9313 Start of enrollment: 2006 Jul 17
Publications & Presentations
PubMed
- 30 citationsTargeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes.Maria Apostolidi, Ioannis A. Vathiotis, Viswanathan Muthusamy, Patricia Gaule, Brandon M. Gassaway
Cancer Research. 2021-06-21 - 110 citationsTumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.Douglas B. Johnson, Mellissa J. Nixon, Yu Wang, Daniel Y. Wang, Emily Castellanos
JCI Insight. 2018-12-20 - 51 citationsWhole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.H Kadara, M Choi, J Zhang, E R Parra, J Rodriguez-Canales
Annals of Oncology. 2017-01-01
Journal Articles
- Siglec-15 as an Immune Suppressor and Potential Target for Normalization Cancer ImmunotherapyDavid L Rimm, Agedi N Boto, Roy S Herbst, Nature
- An International Multicenter Study to Evaluate Reproducibility of Automated Scoring for Assessment of Ki67 in Breast CancerRichard Levenson, David L Rimm, Daniel F Hayes, Chad Galderisi, Liron Pantanowitz, Nature
- Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung CancerGuoping Cai, Sarah B Goldberg, Scott Gettinger, Anne Chiang, Roy S Herbst, David L Rimm, Kurt Schalper, Richard Lifton, Clinical Cancer Research
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Join now to see all
Lectures
- Join now to see all
Authored Content
- HER2-Low, a Separate Entity?December 2022
Press Mentions
- HER2 and Lung Cancer: New Test Holds Great Promise to Help Far More PatientsSeptember 26th, 2024
- 2023 ‘Top Doctors’ List Features Over 250 Yale Medicine PhysiciansMay 3rd, 2023
- Connecticut Magazine’s 2023 “Top Doctors” Issue Recognizes 82 Smilow Cancer Hospital and Yale Cancer Center PhysiciansMay 1st, 2023
- Join now to see all
Grant Support
- Predicting Metastasis In MelanomaNational Cancer Institute2006–2012
- Shared Resources-Critical Technologies For Tissue ServicesNational Cancer Institute2007–2011
- Optimal Predictors Of Response To TrastuzumabNational Cancer Institute2009–2010
- Predicting Metastasis To Lymph NodesNational Cancer Institute2005–2008
- Prediction Of Breast Cancer Response To Hormonal ThearpyNational Cancer Institute2004–2007
- Predicting Metastisis To Lymph NodesNational Cancer Institute2006
- AQUA: A New Quantitative In Situ Proteomic AssayNational Cancer Institute2003–2004
- Establishment And Regulation Of Cell/Cell AdhesionNational Institute Of General Medical Sciences1998–2002
- Value Of MET For Prediction Of Metastasis In CancerNational Cancer Institute1999–2000
- QB Cytology, Method For Detect Circulating Cancer CellsNational Cancer Institute1999–2000
- Molecular Clonality Assay For Early Cancer DiagnosisNational Cancer Institute1999–2000
- Role Of Beta Catenin Activation In Progression And Prognosis Of MelanomaNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1999
External Links
- lab pagehttp://medicine.yale.edu/lab/rimm/david_rimm.profile?source=news
- faculty pagehttp://medicine.yale.edu/pathology/people/david_rimm.profile
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: